One study used retrospective analysis, genotyping SNPs, and arrayed primer extension (APEX) technology in 169 patients receiving high dose melphalan for MM found a polymorphism in APE1 or MUTYH represent independent prognostic factors significantly associated with the shorter survival of MM patients [19]. Here, MUTYH is linked to Miyoshi myopathy.